Literature DB >> 15262209

Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice.

H Fai Poon1, Gururaj Joshi, Rukhsana Sultana, Susan A Farr, William A Banks, John E Morley, Vittorio Calabrese, D Allan Butterfield.   

Abstract

Amyloid beta-peptide (Abeta) is known to induce free radical-mediated oxidative stress in the brain. Free radical-mediated damage to the neuronal membrane components has been implicated in the etiology of Alzheimer's disease (AD). Abeta is produced by proteolytic processing of the amyloid precursor protein (APP). The senescence accelerated mouse prone 8 (SAMP8) strain was developed by phenotypic selection from a common genetic pool. The SAMP8 strain exhibits age-related deterioration in memory and learning as well as Abeta accumulation, and it is considered an effective model for studying brain aging in accelerated senescence. Previous research has shown that a phosphorothiolated antisense oligonucleotide directed against the Abeta region of APP decreases the expression of APP and reverses deficits in learning and memory in aged SAMP8 mice. Consistent with other reports, our previous study showed that 12-month-old SAMP8 mice have increased levels of oxidative stress markers in the brain compared with that in brains from 4-month-old SAMP8 mice. In the current study, 12-month-old SAMP8 mice were treated with antisense oligonucleotide directed against the Abeta region of APP, and the oxidative markers in brain were decreased significantly. Therefore, we conclude that Abeta may contribute to the oxidative stress found in aged SAMP8 mice that have learning and memory impairments. These results are discussed in reference to AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262209     DOI: 10.1016/j.brainres.2004.05.048

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  35 in total

1.  The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model.

Authors:  Masaki Ueno; Bin Wu; Toshitaka Nakagawa; Yukiko Nagai; Masayuki Onodera; Cheng-Long Huang; Takashi Kusaka; Kenji Kanenishi; Haruhiko Sakamoto
Journal:  Histochem Cell Biol       Date:  2010-05-11       Impact factor: 4.304

2.  Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Michael L Niehoff; John E Morley; Albert M Crider; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

3.  Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease.

Authors:  M P Smith; W A Cass
Journal:  Neuroscience       Date:  2006-11-15       Impact factor: 3.590

4.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

Review 5.  Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence.

Authors:  Koji Tomobe; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2009-02-27       Impact factor: 3.996

Review 6.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

7.  Microarray profile of brain aging-related genes in the frontal cortex of SAMP8.

Authors:  Shao-Chun Chen; Gang Lu; Chu-Yan Chan; Yangchao Chen; Hua Wang; David Tai-Wai Yew; Zhong-Tang Feng; Hsiang-Fu Kung
Journal:  J Mol Neurosci       Date:  2009-10-17       Impact factor: 3.444

Review 8.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

Review 9.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Proteomic analysis of brain protein expression levels in NF-kappabeta p50 -/- homozygous knockout mice.

Authors:  Joshua B Owen; Wycliffe O Opii; Charles Ramassamy; William M Pierce; D Allan Butterfield
Journal:  Brain Res       Date:  2008-09-12       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.